Moderna, Inc. — fact timeline

Moderna, Inc. shareholders approved Ratification of appointment of Ernst & Young LLP as independent registered public accounting firm for year ending December 31, 2026 at the 2026-05-06 meeting.

“The Company’s stockholders ratified the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2026, with the votes cast as follows: Votes For Votes Against Abstain 298,823,277 3,406,479 285,923”

Moderna, Inc. shareholders approved Approval, on a non-binding advisory basis, of the frequency of future non-binding advisory votes to approve the compensation of the Company’s named executive officers at the 2026-05-06 meeting.

“The results of the stockholders’ vote to hold an advisory vote to determine the frequency of future stockholder advisory votes on the compensation paid to the Company’s named executive officers were as follows: 1 year 2 years 3 years Abstain 259,590,666 113,043 618,688 281,418”

Moderna, Inc. shareholders approved Approval, on a non-binding advisory basis, of the compensation of the Company’s named executive officers at the 2026-05-06 meeting.

“The Company’s stockholders approved, on an advisory basis, the compensation of the named executive officers. The result of the stockholders’ vote with respect to the approval of the compensation of the named executive officers was as follows: Votes For Votes Against Abstain 169,401,841 90,761,924 440,050 There were 41,911,864 broker non-votes on the proposal.”

Moderna, Inc. shareholders approved Election of Class II directors for a three-year term expiring at the 2029 Annual Meeting at the 2026-05-06 meeting.

“By the vote reflected below, the Company’s stockholders elected each of the following individuals to serve as a Class II director for a three-year term expiring at the Company’s 2029 Annual Meeting of Stockholders and until his or her respective successor is duly elected and qualified, or such director’s earlier death, resignation or removal: Votes For Votes Against Abstain Broker Non-Votes Sandra Horning, M.D. 210,914,932 49,357,015 331,868 41,911,864 Abbas Hussain 256,398,374 4,015,044 190,397 41,911,864”

Moderna, Inc.: Amendment to designate federal district courts as exclusive forum for Securities Act claims (effective 2026-05-06).

“On May 6, 2026 , the Board of Directors (the “Board”) of Moderna, Inc. (the “Company”) approved an amendment to the Company’s Second Amended and Restated By-Laws (the “By-Law Amendment”), effective immediately, to designate the federal district courts of the United States as the sole and exclusive forum for resolving any complaint asserting a cause of action arising under the Securities Act of 1933, as amended, unless the Company consents in writing to the selection of an alternative forum.”

Moderna, Inc. reported first quarter ended March 31, 2026 results: revenue $389 million, net income $(1.3) billion, EPS $(3.40).

“Total revenue for the first quarter of 2026 was $389 million, an increase of $281 million compared to the same period in 2025.”

Moderna, Inc. entered into Settlement Agreement with Arbutus Biopharma Corporation and Genevant Sciences GmbH valued at $950 million noncontingent lump sum payment (effective 2026-03-03).

“On March 3, 2026 (the “Effective Date”), Moderna, Inc. (the “Company”) and ModernaTX, Inc. (together with the Company, “Moderna”) and Arbutus Biopharma Corporation (“Arbutus”), Genevant Sciences GmbH (“Genevant” and, together with Arbutus, “Arbutus/Genevant”), and, solely for certain purposes, Genevant Sciences Ltd., entered into a settlement agreement (the “Settlement Agreement”) to resolve all patent infringement litigation between Moderna and Arbutus/Genevant pending in the U.S. and internationally (the “Litigation”).”

Moderna, Inc. entered into Credit Agreement with Ares Capital Corporation valued at $1,500,000,000 (effective 2025-11-19).

“On November 19, 2025, Moderna, Inc. (the “Company”) entered into a Credit and Guaranty Agreement (the “Credit Agreement”), among the Company, as borrower, certain subsidiaries of the Company, as guarantors, the lenders from time to time party thereto, and Ares Capital Corporation, as administrative agent and collateral agent.”

Moderna, Inc. incurred credit facility of $1,500,000,000 credit facility with Ares Capital Corporation at Term SOFR plus an applicable margin of 5.50% per annum or base rate plus an appl maturing November 24, 2030.

“The Credit Agreement provides for a $1,500,000,000 credit facility of which $600,000,000 will be funded as an initial term loan and $900,000,000 will be available as delayed draw term loans.”

Abbas Hussain was appointed as Director at Moderna, Inc..

“On September 28, 2024, the Board of Directors (the “Board”) of Moderna, Inc. (the “Company”), upon the recommendation of the Nominating and Corporate Governance Committee of the Board, appointed Abbas Hussain to the Board, effective October 2, 2024.”

David M. Rubenstein was appointed as Director at Moderna, Inc..

“On July 19, 2024, the Board, upon the recommendation of the Nominating and Corporate Governance Committee, appointed David M. Rubenstein to the Board, effective August 5, 2024.”

Stephen Berenson resigned as Director at Moderna, Inc..

“On July 19, 2024, Robert Langer and Stephen Berenson each notified Moderna, Inc. (the “Company”) of his resignation from the Board of Directors of the Company (the “Board”), including all committees on which he serves, effective August 5, 2024.”

Robert Langer resigned as Director at Moderna, Inc..

“On July 19, 2024, Robert Langer and Stephen Berenson each notified Moderna, Inc. (the “Company”) of his resignation from the Board of Directors of the Company (the “Board”), including all committees on which he serves, effective August 5, 2024.”

Moderna, Inc.: Amended by-laws to include safeguards and requirements for calling special meetings, contingent on stockholder approval of the special meeting amendment (effective 2024-05-08).

“the Board previously approved a corresponding amendment to the Company’s Second Amended and Restated By-laws (the “By-laws”), subject to stockholder approval of the Special Meeting Amendment, to include safeguards and requirements for calling special meetings”

Moderna, Inc.: Amended certificate of incorporation to provide for exculpation of executive officers as permitted under Delaware law (effective 2024-05-08).

“(ii) a Certificate of Amendment to the Charter to provide for the exculpation of the Company’s executive officers, as permitted under Delaware law”

Moderna, Inc.: Amended certificate of incorporation to provide shareholders holding at least 20% of outstanding shares the right to call a special meeting (effective 2024-05-08).

“the Company’s stockholders approved (i) a Certificate of Amendment to the Company’s Amended and Restated Certificate of Incorporation (the “Charter”) to provide shareholders holding no less than 20% of the Company’s outstanding shares the right to call a special meeting of stockholders”

Moderna, Inc. shareholders approved Management proposal to approve an amendment to the Amended and Restated Certificate of Incorporation to provide stockholders the right to call a special meeting at the 2024-05-06 meeting.

“Management proposal to approve an amendment to the Amended and Restated Certificate of Incorporation to provide stockholders the right to call a special meeting. The Company’s stockholders approved an amendment to the Charter to provide stockholders the right to call a special meeting, as described in”

Moderna, Inc. shareholders approved Ratification of appointment of Ernst & Young LLP as independent registered public accounting firm for year ending December 31, 2024 at the 2024-05-06 meeting.

“The Company’s stockholders ratified the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2024, with the votes cast as follows: Votes For Votes Against Abstain 302,267,645 1,386,579 1,087,955”

Moderna, Inc. shareholders approved Approval, on a non-binding advisory basis, of the compensation of the Company’s named executive officers at the 2024-05-06 meeting.

“The Company’s stockholders approved, on an advisory basis, the compensation of the named executive officers. The result of the stockholders’ vote with respect to the approval of the compensation of the named executive officers was as follows: Votes For Votes Against Abstain 248,175,284 25,923,518 488,279”

Moderna, Inc. shareholders approved Election of Elizabeth Tallett as Class III director at the 2024-05-06 meeting.

“By the vote reflected below, the Company’s stockholders elected each of the following individuals to serve as a Class III director for a three-year term expiring at the Company’s 2027 Annual Meeting of Stockholders and until his or her respective successor is duly elected and qualified, or such director’s earlier death, resignation or removal: For Against Abstain Broker Non-Votes Robert Langer 220,067,098 54,371,254 148,729 30,155,098 Elizabeth Nabel, M.D. 266,133,109 8,295,214 158,758 30,155,098 Elizabeth Tallett 258,746,566 15,688,110 152,405 30,155,098”

Moderna, Inc. shareholders approved Election of Elizabeth Nabel, M.D. as Class III director at the 2024-05-06 meeting.

“By the vote reflected below, the Company’s stockholders elected each of the following individuals to serve as a Class III director for a three-year term expiring at the Company’s 2027 Annual Meeting of Stockholders and until his or her respective successor is duly elected and qualified, or such director’s earlier death, resignation or removal: For Against Abstain Broker Non-Votes Robert Langer 220,067,098 54,371,254 148,729 30,155,098 Elizabeth Nabel, M.D. 266,133,109 8,295,214 158,758 30,155,098”

Moderna, Inc. shareholders approved Election of Robert Langer as Class III director at the 2024-05-06 meeting.

“By the vote reflected below, the Company’s stockholders elected each of the following individuals to serve as a Class III director for a three-year term expiring at the Company’s 2027 Annual Meeting of Stockholders and until his or her respective successor is duly elected and qualified, or such director’s earlier death, resignation or removal: For Against Abstain Broker Non-Votes Robert Langer 220,067,098 54,371,254 148,729 30,155,098”

Moderna, Inc. reported the first quarter ended March 31, 2024 results: revenue $167 million, net income GAAP net loss of $1.2 billion, EPS GAAP diluted EPS of $(3.07). Guidance reaffirmed.

“Moderna Reports First Quarter 2024 Financial Results and Provides Business Updates Reports first quarter revenues of $167 million , GAAP net loss of $1.2 billion and GAAP diluted EPS of $(3.07) Prepares for launches of RSV vaccine and Spikevax® 2024-2025 formula; reaffirms 2024 expected product sales of approximately $4 billion”

Moderna, Inc. reported the fourth quarter and year ended December 31, 2023 results: revenue $2.8 billion, net income $217 million, EPS $0.55. Guidance reaffirmed.

“Posts fourth quarter revenues of $2.8 billion, GAAP net income of $217 million and GAAP diluted EPS of $0.55”

Moderna, Inc. reported 2024 results: revenue approximately $4 billion in product sales in 2024. Guidance reaffirmed.

“Company reiterates 2024 expected product sales of approximately $4 billion, planned return to sales growth in 2025 and expectation to break even in 2026 through product launches and disciplined investment”

Moderna, Inc. reported fiscal year ended December 31, 2023 results: revenue approximately $6.7 billion in product sales.

“On January 8, 2024 , Moderna, Inc. (the “Company”) issued a press release (the “Press Release”) in connection with the Company’s presentation on the same date at the 42nd Annual J.P. Morgan Healthcare Conference. The Press Release contains certain preliminary financial information as of and for the fiscal year ended December 31, 2023. Specifically, the Press Release states that (i) the Company generated approximately $6.7 billion in product sales (unaudited) for the fiscal year ended December 31, 2023 from sales of its COVID-19 vaccine, including recognition of approximately $0.6 billion of deferred revenue related to the Company’s efforts with GAVI, The Vaccine Alliance, and (ii) the Company’s current expectation with respect to its cash, cash equivalents and investments in marketable securities (unaudited) as of December 31, 2023 were in excess of $13 billion.”

Arpa Garay departed as Chief Commercial Officer at Moderna, Inc..

“Arpa Garay, the Company’s Chief Commercial Officer, will be departing the Company, and that effective as of December 8, 2023, Ms. Garay will no longer serve in that role or as an executive officer of the Company.”

Moderna, Inc. reported third quarter ended September 30, 2023 results: revenue $1.8 billion, net income $3.6 billion. Guidance reaffirmed.

“Moderna Reports Third Quarter 2023 Financial Results and Provides Business Updates Third quarter 2023 revenues of $1.8 billion; Company expects 2023 revenues of at least $6 billion”

Moderna, Inc. reported the second quarter of 2023 results: revenue $344 million, net income net loss of $1.4 billion, EPS loss per share of $3.62. Guidance reaffirmed.

“Total revenue for the second quarter of 2023 was $344 million, compared to $4.7 billion in the same period in 2022, mainly due to a decrease in sales of the Company’s COVID-19 vaccine.”

Moderna, Inc. shareholders rejected Shareholder proposal requesting a report on feasibility of transferring intellectual property at the 2023-05-03 meeting.

“Proposal 4. Shareholder proposal requesting a report on feasibility of transferring intellectual property.”

Moderna, Inc. shareholders approved Ratification of appointment of independent registered public accounting firm at the 2023-05-03 meeting.

“Proposal 3. Ratification of appointment of independent registered public accounting firm. The Company’s stockholders ratified the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2023, with the votes cast as follows:”

Moderna, Inc. shareholders approved Approval, on a non-binding advisory basis, of the compensation of the Company’s named executive officers at the 2023-05-03 meeting.

“Proposal 2. Approval, on a non-binding advisory basis, of the compensation of the Company’s named executive officers. The Company’s stockholders approved, on an advisory basis, the compensation of the named executive officers.”

Moderna, Inc. shareholders approved Election of Class II directors at the 2023-05-03 meeting.

“Proposal 1. Election of directors. By the vote reflected below, the Company’s stockholders elected each of the following individuals to serve as Class II directors for a three-year term expiring at the Company’s 2026 Annual Meeting of Stockholders and until his or her respective successor is duly elected and qualified, or such director’s earlier death, resignation or removal:”

Moderna, Inc. reported the first quarter of 2023 results: revenue $1.9 billion, net income $79 million, EPS $0.19. Guidance reaffirmed.

“Moderna Reports First Quarter 2023 Financial Results and Provides Business Updates First quarter 2023 revenues of $1.9 billion; GAAP net income of $79 million and GAAP diluted EPS of $0.19”

Moderna, Inc. reported the fiscal year ended December 31, 2022 results: revenue $19.3 billion, net income $8.4 billion, EPS $20.12. Guidance reaffirmed.

“Full-year 2022 revenues of $19.3 billion; GAAP net income of $8.4 billion and GAAP diluted EPS of $20.12”

Moderna, Inc. reported the fourth quarter ended December 31, 2022 results: revenue $5.1 billion, net income $1.5 billion, EPS $3.61. Guidance reaffirmed.

“Moderna Reports Fourth Quarter and Fiscal Year 2022 Financial Results and Provides Business Updates Fourth quarter 2022 revenues of $5.1 billion; GAAP net income of $1.5 billion and GAAP diluted EPS of $3.61”

Moderna, Inc. reported 2023 results: revenue approximately $5.0 billion. Guidance reaffirmed.

“Reiterating 2023 expected minimum COVID-19 vaccines sales of approximately $5.0 billion from confirmed Advance Purchase Agreements and 2022 contract deferrals”

Moderna, Inc. reported the fiscal year ended December 31, 2022 results: revenue approximately $18.4 billion.

“COVID-19 vaccine sales for 2022 approximately $18.4 billion (unaudited)”

Moderna, Inc. reported third quarter ended September 30, 2022 results: revenue $3.4 billion, net income $1.0 billion, EPS $2.53. Guidance reaffirmed.

“Moderna Reports Third Quarter 2022 Financial Results and Provides Business Updates Third quarter 2022 revenues of $3.4 billion ; GAAP net income of $1.0 billion and GAAP diluted EPS of $2.53”

Jerh Collins was appointed as Chief Technical Operations and Quality Officer at Moderna, Inc..

“The Company further announced that Dr. Jerh Collins, Ph.D., who will join the Company on O ctober 3, 2022, will assume the role of Chief Technical Operations and Quality Officer of the Company, effective January 1, 2023.”

Juan Andres changed role as President, Strategic Partnerships and Enterprise Expansion at Moderna, Inc..

“On September 29, 2022, Moderna, Inc. (the “Company”) announced that Juan Andres, the Company’s Chief Technical Operations and Quality Officer, will transition into a new role as President, Strategic Partnerships and Enterprise Expansion of the Company, effective January 1, 2023.”

David Meline departed as Chief Financial Officer at Moderna, Inc..

“David Meline will retire as the Company’s CFO effective the same date, but will remain as a consultant to the Company to assist with the transition.”

James Mock was appointed as Chief Financial Officer at Moderna, Inc..

“James Mock has been appointed to serve as the Company’s Chief Financial Officer (“CFO”), beginning September 6, 2022.”

David Meline retired as Chief Financial Officer at Moderna, Inc..

“Mr. Meline’s continued service as Chief Financial Officer of the Company and his voluntary retirement from the Company on December 31, 2022”

Jorge Gomez departed as Chief Financial Officer at Moderna, Inc..

“Jorge Gomez departed from the role of Chief Financial Officer of the Company”

David Meline was appointed as Chief Financial Officer at Moderna, Inc..

“David Meline, the Company’s recently retired Chief Financial Officer, will continue as Chief Financial Officer, effective May 11, 2022.”

Jorge Gomez departed as Chief Financial Officer at Moderna, Inc..

“On May 10, 2022, Jorge Gomez departed, effective immediately, from the role of Chief Financial Officer of Moderna, Inc.”

David Meline retired as Chief Financial Officer at Moderna, Inc..

“Following the appointment of Mr. Gomez, David Meline will retire as the Company’s CFO effective the same date, but will remain as a consultant to the Company to assist with the transition.”

Jorge M. Gomez was appointed as Chief Financial Officer at Moderna, Inc..

“On April 11, 2022, Moderna, Inc. (the “Company”) announced that Jorge M. Gomez had been appointed to serve as the Company’s Chief Financial Officer (“CFO”), beginning May 9, 2022.”